
FDA Approves Aducanumab — A Controversial Drug For Alzheimer's
Short Wave
00:00
Intro
This chapter delves into the controversial approval of the Alzheimer's drug aducanumab, or Aduhelm, examining its claimed benefits against skepticism from experts regarding its effectiveness and safety. It also discusses the financial implications of the drug, highlighting concerns about patient accessibility.
Play episode from 00:00
Transcript


